SCHEMBL1562291

SCHEMBL1562291

O=c1ccc2cc(OCc3ccccc3)cc(Br)c2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.60
NPC1 O15118 3/20 0.60
MAOA P21397 2/20 0.60
CA9 Q16790 2/20 0.60
CA12 O43570 2/20 0.60
CA1 P00915 2/20 0.60
CA2 P00918 2/20 0.60
CA4 P22748 2/20 0.60
CA7 P43166 2/20 0.60
MEN1 O00255 1/20 0.60
CA3 P07451 1/20 0.60
CA6 P23280 1/20 0.60
MTNR1A P48039 1/20 0.60
KMT2A Q03164 1/20 0.60
CA14 Q9ULX7 1/20 0.60
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
ALOX5 P09917 1/20 0.50
RAB9A P51151 2/20 0.48
CA5A P35218 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1562285 0.83 MAOB (0.56) MAOBNPC1MAOACA9CA12
SCHEMBL1561343 0.79 CA12 (0.46) NPC1MAOACA9CA12CA1
SCHEMBL1561280 0.79 CA9 (0.53) MAOBNPC1MAOACA9CA12
SCHEMBL5255141 0.78 ALOX5 (0.50) MAOBNPC1MAOACA9CA12
SCHEMBL12710949 0.78 CA9 (0.59) MAOBMAOACA9CA12CA1
SCHEMBL3592957 0.77 MAOB (0.81) MAOBNPC1MAOACA9CA12
SCHEMBL4898966 0.76 ALOX5 (0.59) MAOBNPC1MAOAMEN1KMT2A
SCHEMBL29418792 0.76 ALOX5 (0.59) MAOBNPC1MAOAMEN1KMT2A
7-Benzyloxycoumarin SCHEMBL3901170 0.75 MAOB (1.00) MAOBNPC1MAOACA9CA12
7-Benzyloxycoumarin SCHEMBL29365449 0.75 MAOB (1.00) MAOBNPC1MAOACA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805160-B1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS LILLY CO ELI (US) 2011-04-06 EP disclosed
US-7354951-B2 Substituted benzopyrans as selective estrogen receptor-beta agonists ELI LILLY AND COMPANY (US) 2008-04-08 US disclosed
US-7354951-B2 Substituted benzopyrans as selective estrogen receptor-beta agonists ELI LILLY AND COMPANY (US) 2008-04-08 US disclosed
US-20080064742-A1 Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists ELI LILLY AND COMPANY 2008-03-13 US disclosed
US-20080064742-A1 Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists ELI LILLY AND COMPANY 2008-03-13 US disclosed
EP-1805160-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2007-07-11 EP disclosed
WO-2006044176-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064742-A1 Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists ESR2, GPER1, ESR1 MAOB 1276/4885NPC1 1475/4885MAOA 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.